방사성요오드(I-131) 격리병실 치료 관리를 위한 환자의 체외방사선량률과 상주 보호자의 피폭선량평가 = Evaluation of Caregivers’ Exposed Dose and Patients’ External Dose Rate for Radioactive Iodine (I-131) Therapy Administration in Isolated Ward

다국어 초록 (Multilingual Abstract)

In this study, the radiation dose rate was measured by time and distance and evaluated whether radiation dose rate was suitable for domestic and international discharge criteria. In addition, the radiation dose emitted from the patient was measured with a glass dosimeter to evaluate the exposure dose if the caregiver stays in the isolated ward by placing a humanoid phantom instead of the caregiver at a distance of 1 m from the patient, on the second day of treatment.
After 23 hours of isolation, the radiation dose rates at a distance of 1 m were 20.54 ± 6.21 μSv/h at 2.96 GBq administration and 27.94 ± 12.33 μSv/h at 3.70 GBq administration. The radiation dose rates at a distance of 1 m were 25.90 ± 2.21 μSv/h when 2.96 GBq was administered and 34.22 ± 10.06 μSv/h when 3.70 GBq was administered after 18 hours of isolation. However, if the isolation period is short may cause unnecessary radiation exposure to the third person. The reading of the attached dosimeter from the morning of the second day of treatment until removal was 0.01 to 0.95 mSv, which is a surface dose determined by the International Commission on Radiation Units and Measurements.
And the depth dose was 0.01 to 0.99 mSv. On the second day of treatment, even if the patient caregivers stayed in the isolation ward, the exposure dose of the patient family did not exceed the effective dose limit of 5 mSv recommended by the ICRP and NCRP.

참고문헌 (Reference)

1 문영민, "유리선량계를 이용한 CBCT의 유효선량 측정에 관한 연구" 동아대학교 대학원 2013

2 강인석 ; 안성민, "방사선 개인피폭선량계를 이용한 피폭선량 측정 및 유용성 평가" 한국콘텐츠학회 14 (14): 864-870, 2014

3 정규환 ; 이현국 ; 조운갑 ; 이재기, "고용량 131I 투여환자 퇴원이후 환자 간병인과 환자 가옥의 피폭선량 측정" 대한방사선과학회 33 (33): 149-154, 2010

4 백성민 ; 고성진 ; 김창수 ; 김정훈 ; 강세식, "갑상선암의 고용량 131I 치료 시 입원기간의 최적화방안 연구" 대한방사선과학회 33 (33): 269-276, 2010

5 Commission UNR, "Release of individuals containing unsealed byproduct material or implants containing byproduct material"

6 Agency IAE, "Release of Patients After Radionuclide Therapy, with Contributions from the International Commission on Radiological Protection" International Atomic Energy Agency 2009

7 Schneider S, "Regulatory analysis on criteria for the release of patients administered radioactive material" Nuclear Regulatory Commission 1994

8 Andresen NS, "Radioiodine ablation following thyroidectomy for differentiated thyroid cancer : Literature review of utility, dose, and toxicity" 6 (6): 187-196, 2017

9 "Radioactivity MSC-oPitMoPWHRTAo. Management of radionuclide therapy patients"

10 Sisson TATATRSJC, "Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : Practice recommendations of the American Thyroid Association" 21 (21): 335-346, 2011

11 Abu-Khaled Y, "Radiation exposure from radioactive iodine I-131 in and surrounding the patients' room" 135 (135): 64-68, 2009

12 Gringsby PW, "Radiation exposure from outpatient radioactiveiodine(I-131)therapy for thyroid carcinoma" 283 (283): 2272-2274, 2000

13 Marriott CJ, "Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy" 123 (123): 62-67, 2017

14 Kadhim AA, "Radiation Dose Assessment to Family Members Taking Care of Non-Cancerous Thyroid Patients Treated with I-131 Therapy in Nuclear Medicine Department" 190 (190): 208-216, 2020

15 Valentin J, "Published on behalf of International Commission on Radiological Protection"

16 Director M, "Office of Federal and State Materials and Environmental Management Programs (FSME) Procedure Approval Reviewing the Non-Common Performance Indicator"

17 "Nuclear Safety Commission No. 19 Regulations on Technical Standards such as Radiation Safety Management"

18 박석건, "I-131 치료를 받은 분화갑상선암 환자에서 I-131의 유효반감기" 대한핵의학회 42 (42): 464-468, 2008

19 Ebrahimi M, "Experimental and analytical dose assessment of patient's family members treated with I-131" 3 (3): 292-, 2016

20 LahfiY, "Evaluation of the release criteria from hospital of thyroid carcinoma patient treated with 131I" (4) : 534-538, 2016

21 De Carvalho JWdA, "Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (I-131) Nal, on an outpatient basis, be safe?" 30 (30): 533-541, 2009

22 Howe DB, "Consolidated guidance about materials licenses. Program-Specific Guidance About Medical Use Licenses volume 9" 2008

23 Hennessey JV, "Comments regarding Practice Recommendations of the American Thyroid Association for radiation safety in the treatment of thyroid disease with radioiodine" 22 (22): 336-337, 2012

24 Taghavaee S, "Analysis of the caregiver effective dose during I-131 therapy of thyroid" 14 (14): 1361-, 2018